952182-02-4

Basic information

• Product Name: 1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLIC ACID
• Synonyms: 1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLIC ACID;4-b]pyridine-5-carboxylic acid
• CAS NO: 952182-02-4
• Molecular Formula: C₇H₅N₃O₂
• Molecular Weight: 163.14
• Mol File: 952182-02-4.mol

Chemical Properties

• Boiling Point: 475.1°C at 760 mmHg
• Flash Point: 241.1°C
• Appearance: /
• Density: 1.617g/cm³
• Vapor Pressure: 7.85E-10mmHg at 25°C
• Refractive Index: 1.763
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.24±0.40(Predicted)
• CAS DataBase Reference: 1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLIC ACID(952182-02-4)
• EPA Substance Registry System: 1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLIC ACID(952182-02-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 952182-02-4(Hazardous Substances Data)

Usage

Uses

1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLIC ACID is used as a chemical intermediate for the synthesis of various compounds in the pharmaceutical industry. Its unique structure and reactivity make it a valuable component in the development of new drugs and therapeutic agents.
Used in Pharmaceutical Industry:
1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLIC ACID is used as a building block for the creation of new pharmaceutical compounds, leveraging its chemical reactivity and structural properties to enhance drug efficacy and target specific biological pathways.
Used in Industrial Processes:
1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLIC ACID is used as a component in the production of certain industrial materials, where its chemical properties may contribute to the desired characteristics of the final product, such as stability or reactivity.
Used in Chemical Research:
1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLIC ACID is used as a research tool in academic and industrial laboratories, where its unique structure and properties are studied to gain insights into new chemical reactions and potential applications in various fields.

InChI:InChI=1/C7H5N3O2/c11-7(12)5-1-4-3-9-10-6(4)8-2-5/h1-3H,(H,11,12)(H,8,9,10)

Upstream product

• 1196156-42-9 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid methyl ester 
• 875781-17-2 5-bromo-7-azaindazole 
• 1234616-67-1 1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 
• 875781-15-0 5-bromo-2-fluoro-3-pyridinecarboxaldehyde 
• 1256824-48-2 C₉H₉N₃O₂ 
• 1086423-59-7 ethyl 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b] pyridine-5-carboxylate 
• 227617-16-5 ethyl 4-chloro-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 227617-15-4 4-Hydroxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 

Downstream Products

• 1453175-13-7 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 4-(4-pyrrolidin-1-ylpiperidine-1-sulfonyl)benzylamide 
• 1453176-77-6 4-{[(1H-pyrazolo[3_,4-b]pyridine-5-carbonyl)amino]methyl}benzenesulfonyl chloride 
• 1453176-76-5 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid benzylamide 
• 1453174-45-2 1H-pyrazolo[3,4-b]pyridine-5-carboxyIic acid 4-(1-acetylpiperidine-4-sulfonyl)benzylamide 
• 1362132-18-0 N-{[4-(piperidine-1-sulfonyl)phenyl]methyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 
• 1362149-37-8 N-(4-(phenylsulfonyl)benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 
• 1362133-42-3 C₂₀H₂₀N₆O₃S 
• 1362133-44-5 C₂₀H₂₃N₅O₄S 
• 1453173-90-4 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 4-(4-hydroxypiperidine-1-sulfonyl)benzylamide 
• 1362133-45-6 C₁₉H₂₂N₆O₃S 
• 1453174-77-0 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 4-(4-oxetan-3-ylpiperazine-1-sulfonyl)benzylamide 
• 1453173-69-7 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 4-(morpholine-4-sulfonyl)-benzylamide 
• 1362141-24-9 N-({4-[(3,5-difluorobenzene)sulfonyl]phenyl}methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 
• 1362151-42-5 N-[(4-[[3-(trifluoromethyl)benzene]sulfonyl]phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 

Relevant articles and documents

Zinc Acetate-Promoted Buchwald-Hartwig Couplings of Heteroaromatic Amines

Zinc salts have been shown to promote the Buchwald-Hartwig coupling of azaindoles and azaindazoles with heteroaryl chlorides to provide the corresponding 1-aryl-1H-azaindoles and 1-aryl-1H-azaindazoles. The substrate scope and mechanistic aspects of this reaction were explored.

Heterocyclic benzoyl amide compounds, medicinal composition and use thereof

The invention discloses heterocyclic benzamide compounds with structural characteristics of formula (1) or pharmaceutically acceptable salts or steric isomers or prodrug molecules thereof. The heterocyclic benzamide compounds as well as pharmaceutically acceptable salts thereof can effectively restrain growth of a plurality of tumor cells, can generate inhibiting effect to proteases such as BCR-ABL, c-Kit and PDGFR, can be used for preparing anti-tumor drugs and can be used for overcoming existing drug (Gleevec)-induced drug resistance.

Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib

Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-RafV600E inhibitor therapy for melanoma and colorectal cancer patients. We describe the discovery and structure-activity relationship study of a series of 1H-pyrazolo[3,4-b]pyridine-5-carboxamide analogues as novel dual inhibitors of EGFR and B-RafV600E mutant. One of the most promising compounds, 6a, potently inhibited both of the kinases with IC50 values of 8.0 and 51 nM, respectively. The compound also strongly suppressed the proliferation of a panel of intrinsic and acquired resistant melanoma and/or colorectal cancer cells harboring overexpressed EGFR with submicromolar IC 50 values. Further mechanism investigation revealed that 6a could sustainably inhibit the activation of the MAPK path way in the resistant SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells with EGFR amplification. Our results support the hypothesis that the EGFR/B-Raf V600E dual inhibition might be a tractable strategy to overcome the intrinsic and acquired resistance of melanoma and/or colorectal cancers against the current B-RafV600E inhibitor therapy.

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5- carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Potent, 1H-pyrazolo[3,4-b]pyridine-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using structure-based design techniques. Many of these compounds exhibited nanomolar antiproliferation activities a

AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

AMIDO-BENZYL SULFONE AND SULFONAMIDE DERIVATIVES

Disclosed are certain amido-benzyl sulfone and sulfonamide compounds, pharmaceutical compositions comprising such compounds, land methods of treatment using such compounds.

AMIDO-BENZYL SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment of an NAMPT-mediated disease or condition in a subject, selected from solid or liquid tumor, rheumat

ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES

The present invention relates to certain alkyl- and di-substituted amido-benzyl sulfonamide compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment of NAMPT-mediated disorders, such as diabetes, rheumatoid arthritis,